Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 74Breast 6Endocrine 5Thoracic 4NET 2Gastrointestinal 2Other solid neoplasm 1Other 1Dermatologic 1CNS 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 4Advanced Solid Tumors 4Solid Tumors 2Solid Tumor 2Mesothelioma, Malignant 2Mesothelioma 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Solid Malignancy 1Relapsed Pediatric Solid Tumor 1Cholangiocarcinoma of the Gallbladder 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced Malignant Solid Neoplasm 1Advanced Cancers 1Advanced Cancer 1

Interventions

pembrolizumab 10Nivolumab 5Granulocyte Colony-Stimulating Factor 4atezolizumab 3Ipilimumab 3Ifosfamide 3Etoposide 3tislelizumab 2sargramostim 2durvalumab 2Thiotepa 2Paclitaxel 2Mesna 2Melphalan 2Filgrastim 2Docetaxel 2Cyclophosphamide 2Carboplatin 2Busulfan 2tazemetostat 1spartalizumab 1regorafenib 1pegylated granulocyte colony-stimulating factor 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1etoposide phosphate 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Everolimus × Other solid neoplasm × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡